Table 4.

Results from the biochemical assay after chronic (7x) 1MeTIQ treatment

Treatment	n	DA	DOPAC	3-MT	HVA
FCX
Control	5	510 ± 29	159 ± 7	14 ± 1	155 ± 14
MK-801	7	213 ± 36**	158 ± 10	17 ± 2	121 ± 16
1MeTIQ-7x	5	435 ± 61	81 ± 7***	36 ± 6**	126 ± 8
1MeTIQ-7x + MK-801	5	614 ± 54###	94 ± 8***###	28 ± 4	128 ± 7
Effect of T1 Effect of T2 Interaction of T1 + T2		F(1/18) = 1.28 p = 0.27 F(1/18) = 9.91 p < 0.01 F(1/18) = 21.10 p < 0.001	F(1/19) = 0.58 p = 0.45 F(1/19) = 71.72 p < 0.0011 F(1/19) = 0.73 p = 0.40	F(1/21) = 0.29 p = 0.59 F(1/21) = 12.50 p < 0.001 F(1/21) = 1.48 p = 0.24	F(1/22) = 1.90 p = 0.18 F(1/22) = 0.96 p = 0.34 F(1/22) = 2.48 p = 0.13
HIP
Control	5	25 ± 1	11 ± 1	15 ± 2	17 ± 2
MK-801	8	23 ± 3	17 ± 1*	13 ± 1	21 ± 3
1MeTIQ-7x	6	34 ± 2	10 ± 1	18 ± 2	29 ± 2**
1MeTIQ-7x + MK-801	4	35 ± 7#	10 ± 3#	15 ± 2	21 ± 1
Effect of T1  Effect of T2  Interaction of T1 + T2		F(1/19) = 0.01 p = 0.92 F(1/19) = 9.18 p < 0.01 F(1/19) = 0.73 p = 0.73	F(1/21) = 3.22 p = 0.09 F(1/21) = 4.68 p < 0.05 F(1/21) = 3.27 p =  0.09	F(1/22) = 1.15 p = 0.30 F(1/22) = 2.02 p = 0.17 F(1/22) = 0.19 p = 0.67	F(1/21) = 0.90 p = 0.35 F(1/21) = 5.94 p < 0.05 F(1/21) = 5.53 p < 0.05

DA and its metabolites (DOPAC. 3-MT. HVA) were measured in the Fcx and hippocampus using HPLC. The data were analyzed using two-way ANOVA and a post hoc Duncan’s MRT. The results are shown as the means ± SEM. N = 8–10 rats per group

*p < 0.05; **p < 0.01; ***p < 0.001 indicate significant changes compared to the control; ^#p < 0.05; ^##p < 0.01; ^###p < 0.001 indicate significant changes compared to the model (MK-801) group